Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer
Journal
Asian Pacific Journal of Cancer Prevention
Year
2015
Background
Between October 2012 and February 2015, 25 patients with metastatic colorectal cancer (mCRC) (mean age, 57.0 ± 12.1 years) were granted access to aflibercept via the Aflibercept Named Patient Program at four centers.
Materials & Methods
Here we reported the initial experience of aflibercept / FOLFIRI in combination. We evaluated treatment-related adverse events (AEs), progression-free survival (PFS) and overall survival (OS).
Results
The majority of the patients experienced gastrointestinal toxicity (grade 1-2), with diarrhea (52%), mucositis (52%), and nausea/vomiting (20%) being largely observed. Neutropenia (16%) and febrile neutropenia (8%) were common grade 3-4 hematological events. Aflibercept-related toxicity was managed as per practice guidelines. No grade 5 event was reported. Median PFS was 6.12 months (95% CI, 4.80-7.20) and OS was 12 months (95% CI, 9.80-14.18). The partial response (PR), stable disease (SD), and progressive disease (PD) rates were 25% (95% CI: 23.4-27.0), 37.5% (95% CI: 31.6-43.3), and 37.5% (95% CI: 22.5-52.5), respectively.
Conclusion
Aflibercept/FOLFIRI can be administered safely in a second line setting to Malaysian patients with mCRC, as the AEs experienced were generally reversible and manageable. The safety and efficacy outcomes were consistent with those observed in Western populations.
Resources and Links
Phone Number: +603 2781 4519 / +603 2781 4520
pubmed.ncbi.nlm.nih.gov 27039822
Share the Page
Information
Consultant Name
Dr Mastura Md Yusof
For general questions about clinical trials
Phone Number: +603 2781 4519 / +603 2781 4520
I would like to be a part of tomorrow's breakthrough
Clinical trials are part of research studies involving patient volunteers that are conducted to find safe and effective treatments for a variety of health conditions. They are critical to the advancement of medicine and improving patient health. Participating in clinical trials offers patients the opportunity to try new and effective treatments that could potentially improve their condition while taking part in vital research that can benefit many future patients.
In Pantai Hospital Kuala Lumpur, clinical trials are carried out under our Clinical Research team.
If you would like to participate in any of our clinical trials or would like to know, please provide your information below and we will be in touch with you: